地榆升白片预防含泰素方案化疗患者白细胞减少症的临床观察  

Therapeutic effect of Diyushengbai tablet on preventing leukopenia caused by included Paclitaxel chemotherapy

作　　者：曾昭宇[1] 张西[1] 王小渝[1] 吴康玉[1] 

机构地区：[1]成都市第三人民医院血液肿瘤科,四川成都610031

出　　处：《西部医学》2007年第4期590-591,593,共3页Medical Journal of West China

摘　　要：目的观察地榆升白片预防含泰素方案化疗患者白细胞减少症的疗效。方法使用含泰素方案化疗的恶性肿瘤患者69例,治疗组32例,化疗同时服用地榆升白片,并与单纯化疗的37例作对照,观察两组的外周血白细胞数的变化、粒细胞集落刺激因子(G-CSF)的用量及继发感染发生情况等。结果治疗组化疗后Ⅲ度以上白细胞减少发生率低于对照组,差异有显著意义。治疗组在化疗第14天、21天的白细胞数均高于对照组,二者差异有显著性。两组集落刺激因子用量、白细胞减少继发感染发生例数之间的差异均有统计学意义。结论地榆升白片能有效预防含泰素方案化疗患者白细胞减少症。Objective To observe the clinical effect of Diyushengbai tablet on preventing leukopenia caused by included Paclitaxel chemotherapy. Methods Sixty-nine cases of malignant tumor were randomly divided into two groups, in whom 37 patients were treated by included Paclitaxel regimen （control group） and 32 were treated by Diyushengbai tablet besides included Paclitaxel regimen （treatment group）, with a treatment course of 20 days. Patients were evaluated by white blood cell count, the dose of G-CSF and the secondary infection rate associated with leukopenia. Results Grade 3 and 4 leukopenia occurred in 10 patients （31.25%） in the treatment group, whereas 19 patients （51.35 % ） in the control group. There was a significant difference between them （P〈0. 05）. G-CSF used in the treatment group averaged 2.98± 1.67, and 4. 82±1.56 in the control group （P〈0.01）. There was statistical difference in the incidence of secondary infection between the two groups. Conclusion Diyushengbai tablet is an effective drug used in preventing leukopenia caused by included Paclitaxel chemotherapy.

关 键 词：地榆升白片 化学疗法 白细胞减少症 含泰素化疗方案 

分 类 号：R557.1[医药卫生—血液循环系统疾病]